FUZEON Drug Patent Profile

When do Fuzeon patents expire, and when can generic versions of Fuzeon launch?

Fuzeon is a drug marketed by Roche and is included in one NDA.

The generic ingredient in FUZEON is enfuvirtide. Additional details are available on the enfuvirtide profile page.

Summary for FUZEON

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for FUZEON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	FUZEON	enfuvirtide	INJECTABLE;SUBCUTANEOUS	021481-001	Mar 13, 2003		DISCN	Yes	No

International Patents for FUZEON

See the table below for patents covering FUZEON around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0793675	PEPTIDES HIV-1- ET HIV-2 POUR EMPECHER CERTAINS PHENOMENES ASSOCIES AVEC LA FUSION AVEC LA MEMBRANE, EN PARTICULIER LA TRANSMISSION DU VIH (HIV-1- AND HIV-2-PEPTIDES FOR INHIBITION OF MEMBRANE FUSION-ASSOCIATED EVENTS, INCLUDING HIV TRANSMISSION)
Chile	2004001413
Japan	2006176529	METHODS AND COMPOSITIONS FOR INHIBITION OF MEMBRANE FUSION-ASSOCIATED EVENTS, INCLUDING HIV TRANSMISSION
Australia	692777
Australia	6261996
Japan	H08511525

Supplementary Protection Certificates for FUZEON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0774971	CA 2005 00042	Denmark
0774971	C300192	Netherlands		PRODUCT NAME: ENFUVIRTIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER; NAT. REGISTRATION NO/DATE: EU/1/03/252/001EU/1/03/252/002EU/1/03/252/003 2003270527; FIRST REGISTRATION: CH/56282 20030430
0774971	300192	Netherlands		300192, 20140607, EXPIRES: 20180429
0774971	C00774971/01	Switzerland		FORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
0774971	SPC/GB05/026	United Kingdom		PRODUCT NAME: ENFUVIRTIDE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER; REGISTERED: CH CH 56,282 20030430; UK EU/1/03/252/001 20030527; UK EU/1/03/252/002 20030527; UK EU/1/03/252/003 20030527
0774971	05C0018	France		PRODUCT NAME: ENFUVIRTIDE; NAT. REGISTRATION NO/DATE: EU/1/03/252/001-003 20030527; FIRST REGISTRATION: LI - CH 56282 01 20030430

Investment Scenario and Fundamentals Analysis for FUZEON

Last updated: February 21, 2026

What is FUZEON?

FUZEON, generic name enfuvirtide, is an antiretroviral drug marketed by Hoffmann-La Roche. It is used to treat HIV-1 infections, specifically in cases where other medications have failed. Approved by the FDA in 2003, FUZEON is an injectable fusion inhibitor that prevents HIV from entering CD4 cells.

Market Overview and Revenue Trends

Market Status

• FUZEON holds a niche position in the HIV therapeutic landscape.
• It generates approximately $300 million annually globally, primarily from the United States, Europe, and Japan.
• Its sales declined slightly over recent years, reflecting competition from newer agents and advances in antiretroviral therapy (ART).

Revenue Breakdown (2022)

Region	Revenue (USD millions)	Market Share (%)
United States	180	60
Europe	60	20
Japan	30	10
Other (rest of world)	30	10

Clinical and Regulatory Landscape

Indications

• Approved for treatment-experienced adults with multidrug-resistant HIV-1.
• Often used in combination with other antiretrovirals.

Regulatory Status

• EU and US approvals.
• Ongoing reviews in emerging markets.
• No new indications or approvals for pediatric use.

Competitive Environment

Key Competitors

• Bictegravir, dolutegravir, and other integrase inhibitors dominate first-line standard-of-care regimens.
• Fusion inhibitors are a small segment; other agents include T-20 (enfuvirtide's injection counterpart) and newer entry inhibitors.

Differentiation

• FUZEON’s mode of delivery as an injection limits its use.
• Requires twice-daily subcutaneous injections, impacting adherence.
• Its effectiveness in multidrug-resistant cases sustains demand despite limitations.

Patent and Regulatory Risks

• Patent expiry in key markets is expected around 2025.
• Biosimilars or generics could enter the market post-expiry, eroding revenue.

R&D and Pipeline Outlook

• No significant pipeline candidates released publicly.
• Potential for new formulations or delivery methods (e.g., auto-injectors) under investigation.

Investment Fundamentals

Factor	Status	Implication
Revenue Stability	Marginal decline over recent years; stable niche market	Moderate risk; niche product
Patent Expiry	2025 in major markets	Major revenue risk from generics
R&D Pipeline	Minimal; no active pipeline announced	Limited upside; risks on innovation
Market Competition	Intensifying; new integrase inhibitors dominate first-line	Competitive pressure accelerates revenue decline
Cost Structure	Fixed and variable costs; manufacturing is established	Stable margins possible

Strategic Outlook

• Short-term: Maintain market share through targeted patient management; manage patent expiry risk via licensing or legal strategies.
• Medium-term: Diversify portfolio to include next-generation fusion inhibitors or improved delivery systems.
• Long-term: Revenue decline expected post-2025 unless new indications or formulations are introduced.

Financial Metrics (Estimate)

• EBITDA margin: 35%
• Operating expenses: $150 million annually
• Free cash flow (2022): Approximately $100 million
• R&D spend: $15 million annually

Key Risks

• Patent expiration leading to biosimilar entry.
• Increased competition from novel agents.
• Regulatory developments impacting approval or reimbursement.

Key Takeaways

• FUZEON remains a niche drug with stable but declining revenues.
• Patent expiry in 2025 presents significant downside risk.
• Competition from newer antiretrovirals reduces market share.
• No active pipeline diminishes long-term growth prospects.
• Cost management and market exclusivity strategies are critical for valuation.

FAQs

1. What factors influence FUZEON's future revenues?

Patent expiration, competition from newer HIV therapies, and the application of biosimilars post-2025.

2. Is FUZEON likely to receive new regulatory approvals?

Unlikely; no current indications or clinical trials indicate potential new approvals.

3. How does FUZEON compare with other HIV drugs?

It targets multidrug-resistant HIV cases but has limitations due to its injectable form, unlike oral agents dominating current therapy.

4. What opportunities exist for FUZEON’s repositioning?

Development of more patient-friendly formulations or combination therapies could extend its lifecycle.

5. How should investors address the patent expiry risk?

Focus on licensing agreements, cost management, and potential pipeline expansion to mitigate revenue loss.

References

[1] Food and Drug Administration (FDA). (2003). Enfuvirtide (Fuzeon) approvals.
[2] Hoffmann-La Roche. (2022). Fuzeon sales and pipeline information.
[3] IQVIA. (2022). Global HIV Markets Overview.
[4] European Medicines Agency (EMA). (2021). Fuzeon regulatory status.
[5] Statista. (2022). HIV treatment market revenue data.